# Sapreme Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sapreme-technologies

- Industry: Biotechnology
- Headquarters: Bilthoven, Netherlands
- Website: www.sapreme-technologies.com
- Total disclosed funding: $17M
- Latest round: Series A (Oct 7, 2021)
- Investors on record: 1

## About

Founded in 2016 and based in Bilthoven, Netherlands, Sapreme Technologies BV operates as a biotechnology company that focuses on developing macromolecule therapeutics. In October 2021, Sapreme Technologies BV raised EUR 15 million in series A funding led by new investor Aglaia Oncology Funds. 

Sapreme Technologies offers medical therapeutics technology such as antibody-targeted antisense oligonucleotides (ASOs) for the treatment of cancer and other indications intended to design and enhance targeted biologics delivery. Its proprietary endosomal escape platform, ENDOSCAPE® improves the therapeutic window by enabling access to intracellular targets with minimal toxicity.  

The company intends to use the proceeds from Series A to further scale the platform and advance its internal drug development pipeline.

## Funding rounds

- Series A, Oct 7, 2021, $17M — Aglaia Oncology Funds

## Investors

- Aglaia Oncology Funds (https://capitalatlas.ai/funds/aglaia-oncology-funds) — Series A